Cell-Type-Targeted Mitochondrial Transfer Therapy
World Mitochondria Society is pleased to announce that Professor Botond Roska from the Institute of Molecular and Clinical Ophthalmology IOB, Basel, Switzerland and Temurkhan Ayupov will join Targeting Mitochondria 2026 as a speakers.
They will talk about : Cell-type-targeted mitochondrial transfer therapy.
Prof. Botond Roska and Temurkhan Ayupov just published a great discovery last April in Nature. They developed MitoCatch, a groundbreaking system that enables targeted delivery of healthy mitochondria to specific cell types affected by disease. This innovation is a major step toward precision mitochondrial therapy.
Mitochondrial dysfunction contributes to numerous currently untreatable conditions, including neurodegenerative disorders such as Parkinson’s and Alzheimer’s, optic nerve atrophy, and heart failure. While transplantation of healthy mitochondria has been explored as a potential therapy, conventional methods lack the specificity and efficiency needed to reach disease-affected cells.
MitoCatch overcomes these limitations by using engineered protein binders to link donor mitochondria to target cells. The system employs three complementary strategies: binders on the cell surface (MitoCatch-C), binders on mitochondria (MitoCatch-M), and bispecific binders bridging mitochondria and cell membranes (MitoCatch-Bi). By tuning binder affinity and multivalent interactions, researchers achieved efficient, cell type-specific mitochondrial delivery in human and mouse models across multiple cell types.
For more information about this great study -
Read the whole story in WMS Website Click here
Read the news on LinkedIn
